Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease

Status Completed

Clinical Trial Summary

Retinopathy of prematurity (ROP) is a neovascular retinal disorder of premature born children, characterized by the development of retinal neovascularisation, macular dragging and eventually retinal detachment. ROP is a leading cause for childhood blindness, especially in developing countries. Vascular endothelial growth factor (VEGF) plays an important role in the development of the disease. Recently, the BEAT ROP study tested the efficacy of intravitreal bevacizumab for stage 3 plus ROP in a prospective, controlled, randomized, stratified, multicenter trial. Authors found that bevacizumab showed a significant benefit for Zone I but not Zone II disease, with continuation of peripheral retinal vessel growths after treatment. The authors also concluded that safety could not be assessed due to the small sample size. Other authors raised concerns regarding the results of the BEAT ROP study and the safety of bevacizumab.

The investigators suspected a better safety profile for ranibizumab to treat stage 3 plus ROP. Here we present the outcome of 6 eyes with ROP stage 3 plus treated with a single injection of ranibizumab.

Clinical Trial Description

The outcome of six eyes with ROP stage 3 plus treated with one single intravitreal injection of ranibizumab is presented. Safety issues and side affects are discussed. Follow up was 6 months. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02164604
Study type	Interventional
Source	Kantonsspital Aarau
Contact
Status	Completed
Phase	N/A
Start date	January 2011
Completion date	October 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05043077` - Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening	Phase 4
Completed	`NCT04838665` - Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study	Phase 4
Completed	`NCT04408807` - Stress Induced by Screening for Retinopathy of Prematurity - Should Speculum and Indentation Rather be Avoided	N/A
Recruiting	`NCT03083431` - Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity	Phase 2
Enrolling by invitation	`NCT04985448` - Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
Recruiting	`NCT02090322` - Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1	N/A
Completed	`NCT00872664` - Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids	N/A
Unknown status	`NCT00254176` - Cysteine Supplementation in Critically Ill Neonates	Phase 2/Phase 3
Completed	`NCT06452524` - Prematurity and Ophthalmological Changes
Completed	`NCT04101721` - Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity	Phase 3
Enrolling by invitation	`NCT02050971` - Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates	Phase 1
Terminated	`NCT01335113` - A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity
Active, not recruiting	`NCT00027222` - The Early Treatment for Retinopathy of Prematurity Study (ETROP)	Phase 2/Phase 3
Recruiting	`NCT06109285` - Validation of i-ROP DL to Detect More Than Mild ROP	N/A
Completed	`NCT01861470` - REDEXAM - Reducing Painful Eye Examinations in Preterm Infants	N/A
Completed	`NCT02014454` - Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature	Phase 2
Terminated	`NCT00634972` - Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity	Phase 4
Completed	`NCT05701124` - Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity	Phase 3
Completed	`NCT04092127` - Pain of Premature Babies and RetCam (DOLICAM)
Completed	`NCT04621136` - PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity	Phase 1/Phase 2